This is an updated Joint BMS, IMS, EMAS, RCOG and AMS Position Statement on HRT and breast cancer risk and includes a summary of the evidence on dydrogesterone. We are aware that the statement is likely to be used by healthcare professionals to guide clinical practice and we believe this additional information would be of assistance to healthcare professionals.